

N.B. English translation for convenience purposes only. In the event of discrepancies, the Swedish version shall prevail.

The nomination committee's proposals for Q-linea's annual general meeting 2026

The nomination committee of Q-linea, reg. no. 556729-0217 ("**Q-linea**" or the "**Company**"), has been appointed in accordance with the principles resolved by the annual general meeting 2025 and consists of Öystein Engebretsen (Investment AB Öresund, chairman of the nomination committee), Johan Bygge (chairman of the board of Q-linea), Erika Kjellberg Eriksson (Nexttobe AB) and Ulf Landegren (Landegren Gene Technology AB). In accordance with the principles resolved by the annual general meeting 2025, the nomination committee submits the following proposals for the annual general meeting of Q-linea on 27 May 2026.

Chairman of the annual general meeting

The nomination committee proposes that Johan Bygge be appointed as chairman of the annual general meeting.

Number of board members and auditors

The nomination committee proposes that the number of board members elected by the general meeting shall be seven (7) members, without deputy members.

The nomination committee proposes that a registered accounting firm be elected as auditor of the Company, and that no deputy auditor be appointed.

Election of board members and chairman of the board

The nomination committee proposes the re-election of board members Johan Bygge, Erika Kjellberg Eriksson, Mario Gualano, Sebastian Backlund and Jonas Jarvius, and the new election of Kari Krogstad and Öystein Engebretsen, for a term of office extending until the end of the next annual general meeting. Karin Fischer has declined re-election. Furthermore, the nomination committee proposes the election of Johan Bygge as chairman of the board and the re-election of Mario Gualano as deputy chairman.

Kari Krogstad, born 1964. Kari E. Krogstad assumed the position of CEO of Medistim in September 2009. She has more than 30 years of experience from the biomedical industry and has held commercial leadership roles in the pharmaceutical, biotechnology and medical technology sectors. Before joining Medistim, she worked for 11 years at Dynal, where, following Invitrogen's acquisition in 2005, she also led Invitrogen Dynal in the role of General Manager. Kari E. Krogstad holds a Master of Science (M.Sc.) in molecular biology from the University of Oslo and a business degree from IHM Business School. Kari Krogstad is independent in relation to the Company and its management and in relation to major shareholders. She holds no shares in the Company.

Öystein Engebretsen, born 1980, is Head of Investments at Investment AB Öresund and a board member of Scandi Standard AB. He has extensive board experience and long-standing experience from the finance and investment industry. Öystein holds a Master of Science in Business with a major in Finance from BI Norwegian School of Management, Sandvika/Oslo. Öystein Engebretsen is independent in relation to the Company and its management but not independent in relation to the Company's major shareholders. He holds, directly and indirectly, a total of 106,450 shares in the Company.

The nomination committee considers that the composition of the board meets the independence requirements set out in the Swedish Corporate Governance Code. The nomination committee's reasoned statement regarding the proposed board and information

Commented [AL1]: Vänligen komplettera med information om innehav i Q-linea.

about the proposed board members is available in a separate document published on the Company's website www.qlinea.com.

Remuneration to the board of directors

The nomination committee has, in its preparatory work, evaluated previously resolved remuneration levels for board members against comparable companies. Taking such review and the financial situation into account, the nomination committee has proposed that the remuneration levels for board members and the chairman of the board remain unchanged, and that remuneration for committee work also remain unchanged.

The nomination committee accordingly proposes that board remuneration for the period until the next annual general meeting shall be paid as follows (the remuneration levels for the current year are stated in parentheses):

- Chairman of the board: SEK 500,000 (500 ,000)
- Deputy chairman of the board: SEK 375 ,000 (375,000)
- Other board members: SEK 250,000 (250 ,000)
- Chairman of the audit committee: SEK 90,000 (90 ,000)
- Other members of the audit committee: SEK 45,000 (45 ,000)
- Chairman of the remuneration committee: SEK 40,000 (40 ,000)
- Other members of the remuneration committee: SEK 20,000 (20,000)

The total remuneration to the persons proposed for election by the nomination committee is accordingly proposed to amount to SEK 2,385,000 (2 ,135 ,000).

Remuneration to the auditor

The nomination committee proposes that remuneration to the auditor shall be paid on the basis of approved invoices rendered on a current account basis.

Election of auditor

The nomination committee proposes, in accordance with the recommendation of the audit committee, the re-election of the registered accounting firm Öhrlings PricewaterhouseCoopers AB as auditor of the Company for a term of office extending until the end of the next annual general meeting. Öhrlings PricewaterhouseCoopers AB has announced that the authorised public accountant Lars Kylberg will continue as the auditor in charge.

Establishment of a nomination committee and nomination committee instructions

The nomination committee proposes that the annual general meeting resolves to establish a nomination committee and adopt instructions for the work of the nomination committee ahead of the annual general meeting 2027 in accordance with the principles set out below.

Principles for the appointment of nomination committee members

The general meeting instructs the chairman of the board to contact the three largest shareholders in terms of voting rights according to Euroclear's share register as regards the ownership structure at the opening of trading on 1 September 2026, each of whom shall appoint one member of the nomination committee. In the event that any of the three largest shareholders does not wish to appoint a member of the nomination committee, the fourth largest shareholder shall be asked, and so on, until the nomination committee consists of three members.

The majority of the members of the nomination committee shall be independent in relation to the Company and its management. The CEO or any other member of the company management shall not be a member of the nomination committee. At least one of the members of the nomination committee shall be independent in relation to the shareholder holding the largest number of votes in the Company or any group of shareholders acting in concert in the

Commented [AL2]: Enligt hemsidan består revisionsutskott respektive ersättningsutskott av ordförande + två ledamöter. Om tre personer ingår i varje utskott borde den totala ersättningen bli 2 385 000 kronor.

Commented [CS3R2]: OK

governance of the Company. Board members may be members of the nomination committee but shall not constitute a majority of the members of the nomination committee.

The members of the nomination committee shall be disclosed on the Company's website no later than six months before the next annual general meeting.

The term of office of the appointed nomination committee shall run until a new nomination committee has been appointed pursuant to a mandate from the next annual general meeting.

The nomination committee shall appoint a chairman from among its members. The chairman of the board or any other board member shall not serve as chairman of the nomination committee.

If a member leaves the nomination committee before its work is completed, and if the nomination committee considers it necessary to replace such member, the nomination committee shall appoint a new member in accordance with the principles set out above, but based on Euroclear's printout of the share register as soon as possible after the member has left his or her position. Any change in the composition of the nomination committee shall be disclosed immediately.

Tasks of the nomination committee

The nomination committee shall present proposals for resolutions on the following matters for the annual general meeting 2027:

- a) Election of chairman of the general meeting,
- b) Determination of the number of board members,
- c) Determination of remuneration and other compensation to the board and its committees, with a breakdown between the chairman, deputy chairman and other members,
- d) Determination of remuneration to auditors,
- e) Election of board members, chairman of the board and deputy chairman,
- f) Election of auditors, and
- g) Proposal for principles for the composition and work of the nomination committee ahead of the annual general meeting 2028.

In preparing the proposal regarding the election of board members and chairman of the board, the nomination committee shall apply section 4.1 of the Code as its diversity policy. In all other respects, the nomination committee shall, in preparing proposals for matters for the annual general meeting 2027, comply with the provisions of the Code.

In connection with its assignment, the nomination committee shall otherwise fulfil the duties incumbent on the nomination committee pursuant to the Code.

Working methods of the nomination committee

The nomination committee shall appoint a chairman from among its members. The chairman of the board or any other board member shall not serve as chairman of the nomination committee.

The nomination committee shall meet as often as necessary in order for the nomination committee to fulfil its duties, but no less than once annually. Notice of meetings shall be issued

by the chairman of the nomination committee. If a member requests that the nomination committee be convened for a meeting, such request shall be complied with.

The nomination committee shall constitute a quorum when at least two members are present. The decision of the nomination committee shall be the opinion for which more than half of the members present vote or, in the event of a tied vote, the opinion supported by the chairman of the nomination committee.

Remuneration

No remuneration shall be paid to the members for their work on the nomination committee. The Company shall bear reasonable costs which the nomination committee deems necessary in order for the nomination committee to fulfil its assignment.

Shareholders have had the opportunity to submit proposals and comments to the nomination committee ahead of the annual general meeting 2026.

Uppsala in April 2026

The nomination committee of Q-linea AB (publ)